Literature DB >> 12814990

A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation.

Patti E Gravitt1, Robert D Burk, Attila Lorincz, Rolando Herrero, Allan Hildesheim, Mark E Sherman, Maria Concepcion Bratti, Ana Cecilia Rodriguez, Kathy J Helzlsouer, Mark Schiffman.   

Abstract

Studies investigating human papillomavirus (HPV) viral load as a risk factor in the development of squamous intraepithelial lesions (SILs) and cancer have often yielded conflicting results. These studies used a variety of HPV viral quantitation assays [including the commercially available hybrid capture 2 (HC 2) assay], which differ in their ability to account for differences in cervical cell collection, linear dynamic range of viral load quantitation, and determination of type-specific versus cumulative viral load measures. HPV-16 and HPV-18 viral quantitation using real-time PCR assays were performed to determine whether type-specific viral load measurements that adjust for specimen cellularity result in a different association between viral load and prevalent SIL and cancer, compared with HC 2 quantitation (which does not adjust for cellularity or multiple infections). In general, HPV-16 viral load as measured by real-time PCR increased linearly with increasing grade of SIL while HPV-18 measured using similar techniques increased through low-grade SIL (LSIL), with HPV-18 viral load among high-grade SIL and cancers near the level of cytologically normal women. HC 2 viral load, using the clinical 1.0 pg/ml cut point, differentiated cytologically normal women from women with any level of cytological abnormality (normal versus >/=LSIL) but did not change as lesion severity increased. There was no evidence for plateau of HC 2 at high copy numbers, nor was significant variability in total specimen cellularity observed. However, cumulative viral load measurements by HC 2, in the presence of multiple coinfections, overestimated type-specific viral load. Multiple infections were more common among women with no (32%) or LSIL (51%) [versus 23% in high-grade SIL/cancer], partially explaining the lack of a dose response using a cumulative HC2 viral load measure. The nonrandom distribution of multiple infections by case-control status and the apparent differential effect of viral load by genotype warrant caution when using HC 2 measurements to infer viral load associations with SIL and cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12814990

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  30 in total

1.  The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies.

Authors:  Julia C Gage; Kayode O Ajenifuja; Nicolas A Wentzensen; Akinfolarin C Adepiti; Claire Eklund; Mary Reilly; Martha Hutchinson; Sholom Wacholder; Joe Harford; Amr S Soliman; Robert D Burk; Mark Schiffman
Journal:  Int J Cancer       Date:  2011-08-05       Impact factor: 7.396

2.  Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test.

Authors:  François Coutlée; Danielle Rouleau; Patrick Petignat; Georges Ghattas; Janet R Kornegay; Peter Schlag; Sean Boyle; Catherine Hankins; Sylvie Vézina; Pierre Coté; John Macleod; Hélène Voyer; Pierre Forest; Sharon Walmsley; Eduardo Franco
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

3.  How does tobacco smoke contribute to cervical carcinogenesis?

Authors:  Philip E Castle
Journal:  J Virol       Date:  2008-06       Impact factor: 5.103

4.  Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3.

Authors:  Long Fu Xi; Laura A Koutsky; Philip E Castle; Cosette M Wheeler; Denise A Galloway; Constance Mao; Jesse Ho; Nancy B Kiviat
Journal:  J Natl Cancer Inst       Date:  2009-01-27       Impact factor: 13.506

5.  Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development.

Authors:  Rachel L Winer; Tiffany G Harris; Long Fu Xi; Kathrin U Jansen; James P Hughes; Qinghua Feng; Carolee Welebob; Jesse Ho; Shu-Kuang Lee; Joseph J Carter; Denise A Galloway; Nancy B Kiviat; Laura A Koutsky
Journal:  J Med Virol       Date:  2009-04       Impact factor: 2.327

6.  Impact of improved classification on the association of human papillomavirus with cervical precancer.

Authors:  Philip E Castle; Mark Schiffman; Cosette M Wheeler; Nicolas Wentzensen; Patti E Gravitt
Journal:  Am J Epidemiol       Date:  2009-12-10       Impact factor: 4.897

7.  Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study.

Authors:  Philip E Castle; Patti E Gravitt; Diane Solomon; Cosette M Wheeler; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

8.  Human papillomavirus prevalence, viral load and pre-cancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: a cross-sectional study.

Authors:  Jennifer R Moodley; Deborah Constant; Margaret Hoffman; Anna Salimo; Bruce Allan; Ed Rybicki; Inga Hitzeroth; Anna-Lise Williamson
Journal:  BMC Cancer       Date:  2009-08-07       Impact factor: 4.430

9.  Ultrasensitive quantitation of human papillomavirus type 16 E6 oncogene sequences by nested real time PCR.

Authors:  Socorro Hernández-Arteaga; Rubén López-Revilla
Journal:  Infect Agent Cancer       Date:  2010-05-14       Impact factor: 2.965

10.  Prospective study of HPV16 viral load and risk of in situ and invasive squamous cervical cancer.

Authors:  Karin Sundström; Alexander Ploner; Lisen Arnheim Dahlström; Juni Palmgren; Joakim Dillner; Hans-Olov Adami; Nathalie Ylitalo; Pär Sparén
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-11-15       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.